Another Forest Investor Says $25B Actavis Offer Is Weak

Law360, New York (March 13, 2014, 4:13 PM EDT) -- Another investor in Carl Icahn-backed Forest Laboratories Inc. recently sued the pharmaceutical company in New York court to block generic-drug maker Actavis PLC’s proposed $25 billion acquisition of the company, calling the terms of the deal “grossly inadequate.”

Shareholder Andrew Bailis alleges in a proposed class action that the deal severely undervalues Forest and that the transaction was “carelessly consummated” in an “improper manner” that constitutes a breach of fiduciary duties by the pharmaceutical company’s board of directors.

The suit, filed Tuesday, contends that “the terms...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.